Inhibikase Therapeutics, Inc. (IKT): Total Assets
$181.20M
As of 2025-12-31
$163.59M
As of 2026-06-30
+93.7%
3-year compound annual growth
+65.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $181.20M | +83.8% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $98.60M | +579.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $14.51M | -41.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $24.94M | -41.3% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $42.47M | +187.3% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $14.78M | n/a | 2022-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $181.20M | +83.8% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $172.81M | +291.0% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $191.05M | -39.7% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $169.43M | -7.2% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $165.08M | -10.8% |
Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗